Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pyxis Oncology (PYXS) Change in Accured Expenses: 2024-2025

Historic Change in Accured Expenses for Pyxis Oncology (PYXS) over the last 2 years, with Sep 2025 value amounting to $1.3 million.

  • Pyxis Oncology's Change in Accured Expenses fell 67.29% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.1 million, marking a year-over-year change of. This contributed to the annual value of -$1.7 million for FY2024, which is 88.15% up from last year.
  • According to the latest figures from Q3 2025, Pyxis Oncology's Change in Accured Expenses is $1.3 million, which was up 138.65% from -$3.4 million recorded in Q2 2025.
  • Over the past 5 years, Pyxis Oncology's Change in Accured Expenses peaked at $4.0 million during Q3 2024, and registered a low of -$3.4 million during Q2 2025.
  • In the last 2 years, Pyxis Oncology's Change in Accured Expenses had a median value of -$1.3 million in 2025 and averaged -$720,714.
  • Over the last 5 years, Pyxis Oncology's Change in Accured Expenses had its largest YoY gain of 38.64% in 2025, and its largest YoY loss of 315.59% in 2025.
  • Pyxis Oncology's Change in Accured Expenses (Quarterly) stood at -$2.7 million in 2024, then plummeted by 67.29% to $1.3 million in 2025.
  • Its Change in Accured Expenses was $1.3 million in Q3 2025, compared to -$3.4 million in Q2 2025 and -$1.3 million in Q1 2025.